Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
601 versus ranibizumab in macular edema secondary to BRVO
NCT05520177Phase 3Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of 601 in branch retinal vein occlusion (BRVO), sponsored by 3S Guojian Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
601
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT05520177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520177.